MedTrace Logo

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

NCT06345495 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-11

No results posted yet for this study

Summary

To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

Conditions

Interventions

DRUG

Ruxolitinib

Given by PO

PROCEDURE

Allogeneic Stem Cell Transplantation

Given by Transplant

DRUG

Levetiracetam

Given by PO

DRUG

Eltrombopag

Given by PO

DRUG

Busulfan

Given by IV

DRUG

Romiplostim

Given by IV

DRUG

Fludarabine phosphate

Given by IV

DRUG

Cyclophosphamide

Given by IV

DRUG

Mesna

Given by IV

DRUG

Tacrolimus

Given by IV or PO

Sponsors & Collaborators

Principal Investigators

  • Uday Popat, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2027-01-01
Completion
2029-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06345495 on ClinicalTrials.gov